Personalized chemo dosing may boost CAR T-Cell success in childhood leukemia

NCT ID NCT07223021

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 23 times

Summary

This study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (B-ALL). About 130 participants will be randomly assigned to receive either standard fludarabine dosing or a dose tailored to their body's drug processing. The goal is to see which approach leads to longer periods without leukemia returning or worsening.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Philadelphia (Data Collection Only)

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-••••

  • Cincinnati Children's Hospital Medical Center (Data Collection Only)

    RECRUITING

    Cincinnati, Ohio, 45229, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-••••

    Contact

Conditions

Explore the condition pages connected to this study.